7917 ostrow street, san diego, california 92111-3604

telephone 858-654-2555                                                                        e-mail:  all@anticancer.com

facsimile 858-268-4175                                                                                       www.anticancer.com

 

 


 

For Release at 6:00am EST May 14, 2004

NEWS – NEWS – NEWS

Genetic profile of AntiCancer’s mouse model of prostate cancer predicts recurrence in human prostate cancer patients

 

A recent article in the Journal of Clinical Investigation by Gennadi Glinsky, et al., describes how scientists from AntiCancer Inc. and the Sidney Kimmel Cancer Center, have used AntiCancer’s MetaMouse® model of metastatic human prostate cancer to determine genetic signatures which predict whether patients would have recurrence of prostate cancer. 

 

Existing procedures for prediction of recurrence of prostate cancer, including blood tests such as the prostate specific antigen (PSA) test and other standard pathological examinations that have been used for decades, have limited prognostic capability. AntiCancer’s clinically-relevant MetaMouse® model of prostate cancer, used in the present study, in combination with modern methods of gene profiling have enabled the development of a more discriminating test for predicting prostate cancer recurrence. This new test will be further evaluated in order to make it available on a broad basis.

 

This study is a significant advance in our ability to more accurately predict the clinical outcome of prostate cancer patients. This test will be useful in determining more effective treatment for the disease.  The success of the current study demonstrates the clinical relevance of AntiCancer’s MetaMouse® models.  AntiCancer has similar patient-like MetaMouse® models for all major types of human cancer that are used for the discovery of new drugs and genes for the cure and diagnosis of cancer.

 

AntiCancer, founded in 1984 and based in San Diego, is also developing new drugs for cancer based on genetic engineering, targeting cancer-specific metabolic defects.  The company is also developing other diagnostics for cancer and other diseases as well as gene and stem-cell therapy of cancer, hair growth and other diseases. 

 

For more information, see AntiCancer’s website at www.anticancer.com

or contact Charlene M. Cooper, E-mail:  all@anticancer.com.